Institutional members access full text with Ovid®

Share this article on:

Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission

Watkins, Jennifer D.a,b; Sholukh, Anton M.a,b; Mukhtar, Muhammad M.a,b; Siddappa, Nagadenahalli B.a,b,*; Lakhashe, Samir K.a,b; Kim, Mikyunga,b; Reinherz, Ellis L.a,b; Gupta, Sandeepc; Forthal, Donald N.c; Sattentau, Quentin J.d; Villinger, Francoise,f; Corti, Davideg; Ruprecht, Ruth M.a,b; for the CAVD Project Group

doi: 10.1097/QAD.0b013e328360eac6
Fast Track

Objective: Although passive immunization with anti-HIV-1 Env IgG1 neutralizing monoclonal antibodies (nmAbs) prevented simian–human immunodeficiency virus (SHIV) infection in rhesus monkeys, IgA nmAbs have not been tested. Here, we sought to determine whether human anti-HIV-1 dimeric (d)IgA1, dIgA2, and IgG1 differ in their ability to prevent mucosal R5 SHIV acquisition in rhesus monkeys.

Design: DIgA1, dIgA2, and IgG1 versions of nmAb HGN194 were applied intrarectally in three rhesus monkey groups 30 min before intrarectal SHIV challenge.

Methods: After a control pharmacokinetic study confirmed that nmAb concentrations in rectal fluids over time were similar for all HGN194 isotypes, control and nmAb-treated animals were challenged intrarectally with an R5 SHIV, and viral loads were monitored.

Results: Unexpectedly, dIgA1 provided the best protection in vivo – although all nmAbs showed similar neutralizing activity in vitro. Five out of the six dIgA1-treated rhesus monkeys remained virus-free compared to only one out of six animals given dIgA2 (P = 0.045 by log-rank test) and two out of six rhesus monkeys treated with IgG1 forms of the nmAb (P = 0.12). Protection correlated significantly with virion capture activity by a given nmAb form, as well as inhibition of transcytosis of cell-free virus across an epithelial cell layer in vitro.

Conclusions: Our data imply that dIgA1-mediated capturing of virions in mucosal secretions and inhibition of transcytosis can provide significant prevention of lentiviral acquisition – over and above direct virus neutralization. Vaccine strategies that induce mucosal IgA, especially IgA1, should be developed as a first line of defense against HIV-1, a virus predominantly transmitted mucosally.

aDana-Farber Cancer Institute

bHarvard Medical School, Boston, Massachusetts

cDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, California, USA

dThe Sir William Dunn School of Pathology, University of Oxford, Oxford, UK

eDivision of Pathology, Yerkes National Primate Research Center

fDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA

gHumabs SAGL, Bellinzona, Switzerland.

*Current address: Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30329, USA.

Correspondence to Ruth M. Ruprecht, MD, PhD, Dana-Farber Cancer Institute, 450 Brookline Avenue, JFB-809, Boston, MA 02215, USA. Tel: +1 617 632 3719; fax: +1 617 632 3112; e-mail: ruth_ruprecht@dfci.harvard.edu

Received 9 November, 2012

Revised 22 February, 2013

Accepted 4 March, 2013

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

© 2013 Lippincott Williams & Wilkins, Inc.